These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 19808740

  • 1. 'Time is brain' also in multiple sclerosis.
    Freedman MS.
    Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract] [Full Text] [Related]

  • 2. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry.
    Duodecim; 2002 Oct; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract] [Full Text] [Related]

  • 3. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O.
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Pharmacological treatment of multiple sclerosis].
    Myhr KM.
    Tidsskr Nor Laegeforen; 2010 Mar 11; 130(5):490-2. PubMed ID: 20224616
    [Abstract] [Full Text] [Related]

  • 11. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B, Tremlett H.
    Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408
    [No Abstract] [Full Text] [Related]

  • 12. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F, Kieseier BC.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract] [Full Text] [Related]

  • 13. Current therapeutic recommendations in multiple sclerosis.
    Berger T.
    J Neurol Sci; 2009 Dec 01; 287 Suppl 1():S37-45. PubMed ID: 20106347
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH, Javed A.
    Curr Opin Ophthalmol; 2009 Nov 01; 20(6):476-81. PubMed ID: 19816177
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.